Table 2 BCVA variation observed in the HAWK and HARRIER studies, regardless of baseline BCVA [Source: [10, 13, 14, 16]]
Treatment | BCVA variation | ||
|---|---|---|---|
Mean | SD | Number of patients (N) | |
Brolucizumab (baseline ➔ 52 weeks) | 6.50 | 13.35 | 730 |
Aflibercept (baseline ➔ 52 weeks) | 7.12 | 13.51 | 729 |
Brolucizumab (52 ➔ 96 weeks) | −0.61 | 7.18 | 730 |
Aflibercept (52 ➔ 96 weeks) | −1.05 | 8.09 | 729 |